#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
A comprehensive systematic review published in The Lancet Psychiatry examined 54 clinical trials involving over 2,400 participants to evaluate the efficacy of cannabis-based treatments for psychiatric conditions and found minimal to no significant clinical benefit across measured outcomes. This meta-analysis synthesizes the current evidence base for a therapeutic area where clinical demand and patient interest often outpace the quality of supporting evidence. The findings carry important implications for clinicians counseling patients with psychiatric conditions who may be considering or requesting cannabis as a treatment option, particularly given the potential risks associated with cannabis use in vulnerable populations. This evidence gap is particularly relevant in regions where medical cannabis has been legalized, as clinicians may face pressure to recommend or approve cannabis despite limited proof of psychiatric benefit. Clinicians should use these findings to inform informed consent discussions with patients, emphasizing the lack of robust evidence for psychiatric indications and discussing established, evidence-based alternatives instead.
“After two decades of seeing patients and following the evidence closely, I can tell you that the psychiatric data simply doesn’t support cannabis as a first-line treatment for mood or anxiety disorders, and we need to be honest about that with our patients rather than chase anecdotal reports. What this review confirms is that we should reserve cannabis for carefully selected cases where conventional options have failed, and even then, we’re working with limited evidence on optimal dosing and long-term outcomes.”
💊 While cannabis-based treatments have generated considerable clinical interest for psychiatric conditions, a recent systematic review in The Lancet Psychiatry examining 54 trials involving over 2,400 participants found minimal to no significant benefit for psychiatric symptoms, which represents an important reality check amid expanding legalization and patient demand. The evidence gap is particularly notable given substantial heterogeneity in study designs, dosing regimens, cannabinoid ratios (THC:CBD), outcome measures, and patient populations, making it difficult to identify which patients, if any, might benefit from specific formulations. Additionally, most trials were small and short-term, potentially missing delayed effects or requiring longer exposure periods, and publication bias may favor positive findings, further clouding the evidence base. Clinicians should acknowledge patient perspectives on cannabis while maintaining realistic expectations about psychiatric symptom improvement and remain vigilant for potential harms including psychosis risk in vulnerable populations and cannabis use disorder, particularly given
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: